Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 10, 2023, Unity Biotechnology, Inc. (the "Company") and Jamie Dananberg
agreed that Dr. Dananberg would be leaving his employment with the Company on
April 30, 2023. Under the Employment Agreement dated January 29, 2018 between
the Company and Dr. Dananberg, as amended, in the event Dr. Dananberg timely
delivers a release of claims to the Company, he will receive, in addition to any
accrued obligations, (i) a severance payment equal to nine months of his base
salary and (ii) continued health care coverage for himself and his covered
dependents under the provisions of the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended, until the earlier of the nine month
anniversary of his separation date or the date he becomes eligible for
healthcare coverage from another employer. Dr. Dananberg is also eligible to
enter into a consulting agreement with the Company that provides for service as
a consultant until December 31, 2023 in exchange for consideration to include
continued vesting of his equity awards.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses